A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 8, 2006, Pages 1693-1700

  Simonneau, Gerald ^a   Laporte, S ^b   Mismetti, P ^b   Derlon, A ^c   Samii, K ^d   Samama, C M ^e   Bergman, J F ^f  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b SERVICE DE NEUROLOGIE   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e AVICENNE HOSPITAL   (France)

^f HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Cancer surgery; Low molecular weight heparin; Venous thromboembolism

Indexed keywords

ENOXAPARIN; NADROPARIN; PLACEBO;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; LEG COMPRESSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHLEBOGRAPHY; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; THROMBOSIS PREVENTION; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; COLORECTAL NEOPLASMS; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; NADROPARIN; POSTOPERATIVE COMPLICATIONS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 33746653728     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02083.x     Document Type: Article

References (23)

1. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson Jr FA, Wheeler HB. Prevention of venous thromboembolism. Chest 2001; 119: 132S-75S.
2. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S.
3. Bergqvist D. Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery. Br J Surg 2004; 91: 965-74.
4. Becchi G, Bonomo GM, Scattarella M, Catania G, Salanitri T, Palazzini E. Dose-effect relationship in the prevention of post-surgical thromboembolism by a low molecular weight heparin. Acta Therap 1993; 19: 163-79.
5. Bounameaux H, Huber O, Khabiri E, Schneider PA, Didier D, Rohner A. Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin. Arch Surg 1993; 128: 326-8.
6. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallbook T, Hedberg M, Horn A, Kelty E, Kvitting P, Lindhagen A, Ljungström KG, Mätzsch T, Risberg B, Syk I, Törngren S, Wellander E, Örtenwall P. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995; 82: 496-501.
7. Azorin JF, Regnard JF, Dahan M, Pansart M et les investigateurs du Groupe Thorax. Efficacy and safety of Fraxiparine in the prevention of thrombo-embolic events in lung cancer surgery. Ann Cardiol Angeiol 1997; 46: 341-7.
8. Cohen AT, Wagner MB, Mohamed MD. Risk factors for bleeding in major abdominal surgery using heparin thromboprophylaxis. Am J Surg 1997; 174: 1-5.
9. Mismetti P, Laporte S, Darmon JY, Buchmüller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001; 88: 913-30.
10. Borly L, Wille-Jorgensen P, Rasmussen MS. Systematic review of thromboprophylaxis in colorectal surgery - an update. Colorectal Dis 2005; 7: 122-7.
11. The European Fraxiparin Study Group. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 1988; 75: 1058-63.
12. Enoxacan Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997; 84: 1099-103.
13. McLeod RS, Geerts WH, Sniderman KW, Greenwood C, Gregoire RC, Taylor BM, Silverman RE, Atkinson KG, Burnstein M, Marshall JC, Burul CJ, Anderson DR, Ross T, Wilson SR, Barton P; Canadian Colorectal Surgery DVT Prophylaxis Trial investigators. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery. Results of the Canadian Colorectal DVT Prophylaxis Trial: A randomized, double-blind trial. Ann Surg 2001; 233: 438-44.
14. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ; CONSORT Group. Reporting of noninferiority and equivalence randomized trials. JAMA 2006; 295: 1152-60.
15. Committee for Proprietary Medicinal Products (CPMP). Points to Consider on Switching Between Superiority and Non-Inferiority. The European Agency for the Evaluation of Medicinal Products. London: CPMP/EWP/482/ 99, 2000.
16. Committee for Proprietary Medicinal Products. Points to Consider on Clinical Investigation of Medicinal Products for Prophylaxis of Intra- and Postoperative Venous Thromboembolic Risk. The European Agency for the Evaluation of Medicinal Products. London: CPMP/EWP/707/98, 2000.
17. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M; PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005; 92: 1212-20.
18. Wiig JN, Solhaug JH, Bilberg T, Bjerkeset T, Edwin B, Gruner OP, Havig O, Holter O, Knudsen G, Lundblad R, Myrvold HE, Rossi P, Lund H, Kjærgaard P. Prophylaxis of venographically diagnosed deep vein thrombosis in gastrointestinal surgery. Multicentre trials 20 mg and 40 mg enoxaparin versus dextran. Eur J Surg 1995; 161: 663-8.
19. Nurmohamed MT, Verhaeghe R, Haas S, Iriarte JA, Vogel G, van Rij AM, Prentice CR, ten Cate JW. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg 1995; 169: 567-71.
20. Wicky J, Couson F, Ambrosetti P, Didier D, Rohner A, Bounameaux H. Postoperative deep venous thrombosis (DVT) and low-molecular weight heparin (LMWH) type and dosage. Thromb Haemost 1993; 69: 402-3.
21. Fareed J, Bick R. Differentiation of low-molecular-weight heparins: practical implications. Clin Appl Thromb Hemost 2004; 10: 299-300.
22. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975-80.
23. Samama CM, Albaladejo P, Benhamou D, Bertin-Maghit M, Bruder N, Doublet JD, Laversin S, Leclerc S, Marret E, Mismetti P, Samain E, Steib A. Venous thromboembolism prevention in surgery and obstetrics: Clinical practice guidelines. Eur J Anaesthesiol 2006; 23: 95-116.